The state of New Jersey currently has 3 active clinical trials seeking participants for Hepatitis B research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/17/2024
Locations: New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey
Conditions: Hepatitis B, HIV Infections
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Recruiting
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2024
Locations: Investigative Site, Hillsborough, New Jersey
Conditions: Hepatitis B, Chronic
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Hepatitis B, Hepatitis, Liver Diseases